| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,867 |
14,322 |
$644K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,864 |
5,105 |
$283K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
7,484 |
6,555 |
$283K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
13,313 |
11,316 |
$173K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,781 |
1,732 |
$131K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,522 |
1,463 |
$109K |
| S8301 |
Infection control supplies, not otherwise specified |
6,278 |
5,244 |
$103K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,424 |
3,377 |
$97K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,139 |
1,109 |
$87K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
6,989 |
3,053 |
$78K |
| 99429 |
|
1,306 |
1,270 |
$42K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
319 |
300 |
$24K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,871 |
2,377 |
$23K |
| 99000 |
|
1,450 |
1,344 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,193 |
856 |
$13K |
| 92558 |
|
1,717 |
1,662 |
$11K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
175 |
171 |
$10K |
| 87807 |
|
855 |
788 |
$9K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
208 |
198 |
$8K |
| 90461 |
|
2,482 |
2,092 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
88 |
82 |
$6K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
501 |
476 |
$5K |
| 99381 |
|
64 |
62 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
137 |
131 |
$4K |
| 92550 |
|
139 |
138 |
$2K |
| 99050 |
|
171 |
164 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
979 |
683 |
$1K |
| 99383 |
|
14 |
14 |
$1K |
| 0071A |
|
29 |
28 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
25 |
24 |
$821.38 |
| 87428 |
|
14 |
14 |
$378.68 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
2,563 |
2,471 |
$340.38 |
| 96160 |
|
179 |
171 |
$321.75 |
| 92552 |
|
55 |
53 |
$208.25 |
| 99051 |
|
120 |
119 |
$194.22 |
| 90686 |
|
375 |
369 |
$19.35 |
| 81003 |
|
14 |
12 |
$19.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
13 |
12 |
$2.23 |
| 90677 |
|
384 |
371 |
$0.44 |
| 90651 |
|
65 |
62 |
$0.04 |
| 90620 |
|
12 |
12 |
$0.01 |
| 90670 |
|
986 |
961 |
$0.00 |
| 99173 |
|
1,979 |
1,909 |
$0.00 |
| 90710 |
|
443 |
434 |
$0.00 |
| 90734 |
|
27 |
27 |
$0.00 |
| 90633 |
|
457 |
444 |
$0.00 |
| 90681 |
|
104 |
100 |
$0.00 |
| 90715 |
|
33 |
32 |
$0.00 |
| 90648 |
|
45 |
45 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
59 |
44 |
$0.00 |
| 90680 |
|
629 |
613 |
$0.00 |
| 90723 |
|
232 |
227 |
$0.00 |
| 90696 |
|
71 |
71 |
$0.00 |
| 90698 |
|
60 |
59 |
$0.00 |
| 90697 |
|
443 |
435 |
$0.00 |
| 91307 |
|
40 |
35 |
$0.00 |
| 90656 |
|
97 |
95 |
$0.00 |
| 90647 |
|
38 |
37 |
$0.00 |
| 90619 |
|
29 |
29 |
$0.00 |